Treating Venous Thromboembolism in Patients With Cancer: 2019 Clinical Practice Guidelines
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
Thrombotic Disorders
THROMBOTIC DISORDERS
FEATURE
LATEST ARTICLES
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
Mental Health Impairment in Acute Thrombotic Thrombocytopenic Purpura
At a median follow-up of 36 months, patients with acute thrombotic thrombocytopenic purpura displayed impaired quality of life compared with the general population.
FDA Approves Earlier Use of Nplate in Immune Thrombocytopenia
The FDA has approved the supplemental Biologics License Application for Nplate (romiplostim; Amgen) to expand treatment to newly diagnosed adult patients with immune thrombocytopenia.
Study Compares Anticoagulants for Antiphospholipid Syndrome
Authors find rivaroxaban not noninferior to vitamin K antagonists for secondary thromboprophylaxis
Risk for Pulmonary Embolism Elevated for up to 18 Weeks After Surgery
Current guidelines recommend 5 weeks of postoperative prophylactic anticoagulation, but a new study suggests the duration of this treatment ought to be extended.
Rivaroxaban May Be the Best Strategy for Deep Vein Thrombosis Prevention in Total Knee Replacement
A review and meta-analysis of 25 randomized controlled trials showed that single-agent treatment strategies were generally more effective than combination strategies.
Analysis of Thrombotic Events in Patients Receiving Ibrutinib
Researchers found a low incidence of thrombotic events in patients receiving ibrutinib, though some patients still experienced bleeding.
Few Differences Found in Outcomes With Various Venous Thromboembolism Prophylaxis Protocols
Researchers found that most instances of venous thromboembolism occurred while patients were receiving prophylaxis.
Efficacy of Splenectomy Following Treatment Failure in Immune Thrombocytopenic Purpura
Splenectomy is often administered as third- or fourth-line therapy, but earlier administration may mitigate treatment-related complications.
Risk of Stroke Following an Episode of Acute TTP Seen With Low ADAMTS13 Activity
Stroke occurred in no patients with normal ADAMTS13 activity but did occur in 27.6% of patients with ADAMTS13 activity below 70%, the cutoff for normal activity.
Long-Term Venous Thromboembolism Risk Following Blood or Marrow Transplantation for Non-Hodgkin Lymphoma
Risk for late-occurring thromboembolism was elevated in patients who underwent allogeneic transplantation, and risk factors varied by transplantation type.
Rivaroxaban Compared With Warfarin in Morbidly Obese Patients With VTE
Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
Low-Intensity Warfarin Did Not Meet Noninferiority for Preventing VTE or Death in GIFT Trial
Researchers assessed the efficacy of a target international normalized ratio of 1.8 compared with the standard of 2.5 for thromboprophylaxis following arthroplasty.
The Role of Vitamin K Antagonists in Managing Thrombosis in Myeloproliferative Neoplasms
Long-term oral anticoagulation with vitamin K antagonists is recommended for most patients with myeloproliferative neoplasms experiencing thrombosis.
New Score For Predicting VTE Risk in Multiple Myeloma Outperforms Current Guidelines
A new risk stratification score for venous thromboembolism was developed and validated in a cohort of more than 4000 patients with multiple myeloma.
Investigation of the Causes of Extreme Thrombocytosis
Common causes of extreme thrombocytosis differed in inpatient and outpatient settings, according to a review of 44,490 patient records.
Thrombopoietin Agonists Offer Best Efficacy and Safety in Persistent Adult Immune Thrombocytopenia
Eltrombopag and romiplostim demonstrated superior response compared with rituximab for persistent adult immune thrombocytopenia.
Efficacy and Safety of Direct Oral Anticoagulant Therapy for Venous Thromboembolism
Rates of recurrence and bleeding were similar between the 3 treatments assessed, but rivaroxaban demonstrated lower mortality rates.
Guideline Update for Venous Thromboembolism Prophylaxis in Patients With Cancer
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Clinical Benefit of Oral Anticoagulants May Outweigh Risk of Bleeding in Patients With Atrial Fibrillation
Reinitiation of oral anticoagulant therapy may be warranted for some patients with atrial fibrillation who have a high risk of bleeding.
VWF High-Molecular-Weight Multimer Deficiency Associated With Neurological Symptoms in TTP
Researchers assessed whether loss of von Willebrand factor high-molecular-weight multimers was predictive of morbidity in thrombotic thrombocytopenic purpura.
A Patient-Centered Model of Congenital Thrombotic Thrombocytopenic Purpura Symptoms and Effects
Researchers interviewed clinicians and patients to develop a conceptual model of congenital thrombotic thrombocytopenic purpura.
Revisiting Guidelines on the Use of Direct Oral Anticoagulants in Obese Patients With Atrial Fibrillation
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation.
Evans Syndrome: Incidence, Prevalence, and Survival
Patients with secondary Evans syndrome demonstrated increased mortality compared with all other cohorts.
Direct Oral Anticoagulants Show Similar Efficacy Compared With Warfarin in Morbidly Obese Patients
Incidences of recurrent thromboembolism and major bleeding did not significantly differ between patients receiving DOACs and patients receiving warfarin.
A New Standard of Care for Immune-Mediated Thrombotic Thrombocytopenic Purpura?
Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term.
Underlying Connective Tissue Disorders in TTP Result in Longer, More Expensive Hospitalizations
A higher proportion of black patients and female patients with thrombotic thrombocytopenic purpura had coexisting connective tissue disorders.
Increased Risk for Venous Thromboembolism in Patients Receiving Anticoagulant Therapy for Pulmonary Embolism
Researchers assessed incidence of recurrent thromboembolism and major bleeding in patients with cancer and incidental pulmonary embolism.
New Treatment Options Needed for Immune Thrombocytopenia
Current treatment strategies for immune thrombocytopenic purpura are centered on immunomodulation and decreasing platelet destruction
Extended Oral Anticoagulation Therapy for First Unprovoked Deep Vein Thrombosis
Continuing warfarin therapy for 18 months after an initial 6-month course decreased incidence of venous thrombosis and major bleeding.
Dabigatran Safe, Effective for Managing VTE in Pediatric Trials
The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Rivaroxaban May Be Safe, Effective for Pediatric VTE Treatment, Says Study
Results of the study showed that the rate of symptomatic recurrent VTE – the primary end point – was similar in both treatment groups with 1.2% of patients experiencing a recurrent event in the rivaroxaban group compared with 3.0% in the standard anticoagulation group.
Using the PLASMIC Score to Risk Stratify Patients With Immune Thrombotic Thrombocytopenic Purpura
Utilizing a PLASMIC score-based algorithm may reduce treatment costs by reducing overutilization of therapeutic plasma exchange and expert consultations.
From Fatal to Curable: Immune-Mediated Thrombotic Thrombocytopenic Purpura
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
Relapse Predictors in Immune Thrombotic Thrombocytopenic Purpura After Rituximab Treatment
Rituximab treatment conferred short-term benefit against subsequent relapse, though this benefit decreased over time.
Heterozygous FXII Deficiency Appears Unrelated to the Incidence of Thrombotic Events
Similar rates of thrombotic events occurred in patients with FXII deficiency and unaffected controls.
Low Antigen Level May Be an Indication for Splenectomy in Relapsing Thrombotic Thrombocytopenic Purpura
Researchers described 2 patients with refractory thrombotic thrombocytopenic purpura who regained normal ADAMTS13 levels after splenectomy.
Equivalence Between Rituximab Originator and Biosimilar in Immune Thrombocytopenic Purpura
Platelet counts, ADAMTS13 recovery, and infective complications were not significantly different between the 2 treatment groups.
Managing Pediatric Systemic Lupus Erythematosus in Thrombotic Thrombocytopenic Purpura
Researchers recommended performing lactate dehydrogenase level and blood smear testing in patients with renal and neurological symptoms.
Risk Factors for Recurrent Venous Thromboembolism in Patients With Sickle Cell Disease
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
Caplacizumab Associated With Improved Outcomes in Acquired Thrombotic Thrombocytopenic Purpura
Patients receiving caplacizumab experienced faster normalization of platelet count and fewer adverse events compared with patients on placebo.
Decreased Relapse, Mortality Rates With Rituximab in Acquired Thrombotic Thrombocytopenic Purpura
Researchers conducted a meta-analysis of 9 studies in patients receiving either rituximab or conventional treatment for TTP.
Second-Line Treatment Outcome Variability in Children With Immune Thrombocytopenia
Though all evaluated second-line treatments improved clinical outcomes, romiplostim was found to be the most effective at 6 months.
VTE-BLEED Risk Score Reliably Identifies Patients With PE at Risk for Major Bleeding
The VTE-BLEED risk score identified patients with pulmonary embolism at risk for in-hospital majorbleeding.
Outcomes With Eculizumab and Responses to Withdrawal for Atypical Hemolytic Uremic Syndrome
Among patients who underwent eculizumab withdrawal, 76.9% remained in remission during the course of the study.
Using Neural Networks to Assess Risk for Deep Vein Thrombosis
The neural network developed in this study yielded a false-negative rate of 0.22%.
Direct-Acting Oral Anticoagulant Treatment for Acute Venous Thromboembolism
Although clinical trials are ongoing, the safety profile and net clinical benefit of DOACs for acute venous thromboembolism treatment are unclear.
Optimal Approaches to Treating Venous Thromboembolism in Patients With Cancer
Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.
Long-Term Outcomes of Fostamatinib for Immune Thrombocytopenia
Researchers reviewed outcomes from several phase 3 trials assessing the feasibility of fostamatinib for immune thrombocytopenia.
Managing Neonatal Thrombocytopenia of Alloimmune Origin
A French working group developed a treatment algorithm for diagnosis and treatment of neonatal thrombocytopenia of suspected or confirmed alloimmune origin.
Want to read more?
Please login or register first to view this content.
Next post in Thrombotic Disorders
